Biosimilars approved in Ecuador

Biosimilars/General | Posted 28/01/2022 post-comment0 Post your comment

In Ecuador, the regulatory body for the approval of biologicals is the National Agency for Regulation, Control and Health Surveillance (ARCSA).

ARCSAV22A28

ARCSA was created in August 2012 and is responsible for the regulation, technical control and sanitary surveillance of the following products: processed foods, food additives, medicines in general, nutraceutical products, biological products, processed natural products for medicinal use, homeopathic medicines and dental products; medical devices, biochemical and diagnostic reagents, and other hygienic products, pesticides for domestic and industrial use, manufactured in the national territory or abroad, for import, export, commercialization, dispensing and selling.

In 2019, ARCSA finalized the regulatory guidelines on biosimilars. The legal framework for biosimilar medicines is established according to the Regulation for Obtaining Health Registration of Biological Medicines No. 00385-2019, which includes biotechnological and biosimilar medicines. The purpose of this regulation is to regulate, control and monitor in the country the production and commercialization of biological medicines/drugs for human use and consumption, in order to guarantee their quality, safety and efficacy, as well as to establish the general procedure for obtaining the health registration.

ARCSA defines biosimilar drug as a biological drug that has demonstrated through the comparability exercise that it is similar to the reference biological drug in terms of quality, safety and efficacy.

To date, ARCSA has approved four biosimilars [1] within the product classes of: 1) erythropoiesis-stimulating agent; 2) granulocyte colony-stimulating factor (G-CSF); 3) tumour necrosis factor (TNF) inhibitor for use in Ecuador, see Table 1.

Table 1: Biosimilars approved by ARCSA
Product name Active substance Therapeutic area Manufacturer/Company name
Ior Leukocim filgrastim Neutrofilia
Neutropenia
Centro de Inmunologia Molecular (CIM)
Remsima infliximab Ankylosing spondylitis
Crohn's disease
Psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Ulcerative colitis
Celltrion
Zarzio filgrastim Cancer
Haematopoietic stem cell transplant
Neutropenia
Sandoz
Data updated on 28 January 2022.
Source: ARCSA.

 

Five biomimics are also approved in Ecuador:
1. Epogen, Hemastin, Ior Epocim, erythropoietin biomimics, for the treatment of anaemia.
2. Etanar, etanercept biomimic, for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis.
3. Reditux/Tidecron, a biomimic of rituximab, for the treatment of rheumatoid arthritis, non-Hodgkin's lymphoma and leukaemia.

Biomimics are intended copies, unregulated biologicals, biocopies, which cannot be considered biosimilars unless they have been reviewed and approved by the appropriate regulatory agencies in accordance with the international guidelines provided by the World Health Organization (WHO) for the approval of biosimilars [2].

Editor’s comment
European Medicines Agency regulatory requirements ensure the same high standards of quality, safety, and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product but they are not universally accepted by regulatory bodies outside of the European Union (EU). It should be noted that ‘biosimilars’ approved in Ecuador might not have been authorized if they had been subjected to the strict regulatory processes required for approval of biosimilars in the EU.

Related articles
The biosimilars market in Latin America: a summary

Similar biotherapeutic products approved and marketed in Latin America

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Diferencias en inmunogenicidad, farmacovigilancia y documentos legales en productos biológicos en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Diferencias en inmunogenicidad, farmacovigilancia y documentos legales en productos biológicos en América Latina

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

References
1. Ortiz-Prado E, Ponce-Zea J, Vasconez JE, et al. Current trends for biosimilars in the Latin American market. Generics Biosimilars Initiative Journal. (GaBI Journal). 2020;9(2):64-74. doi:10.5639/gabij.2020.0902.011
2. GaBI Online - Generics and Biosimilars Initiative. Glosario de términos principales [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jan 28]. Available from: www.gabionline.net/es/biosimilares/general/glosario-de-terminos-principales

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

Source: ARCSA

comment icon Comments (0)
Post your comment
Related content
Promotion of biosimilar product development in Puerto Rico
Biological 143606710 V14J14ct
Biosimilars/General Posted 17/10/2023
CVS’ Cordavis to launch Sandoz’s Hyrimoz (adalimumab)
15 AA010699
Biosimilars/General Posted 03/10/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010